

1 **Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test**

2

3 Carmen W.E. Embregts¹, Babs Verstrepen², Jan A.M. Langermans,^{2,3} Kinga P. Böszörményi²
4 Reina S. Sikkema¹, Rory D. de Vries¹, Donata Hoffmann⁴, Kerstin Wernike⁴, Lidwien A.M.
5 Smit⁵, Shan Zhao⁶, Barry Rockx¹, Marion P.G. Koopmans¹, Bart L. Haagmans¹, Thijs Kuiken¹,
6 Corine H. GeurtsvanKessel¹

7

8

9 ¹ Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands

10 ² Biomedical Primate Research Centre, Rijswijk, the Netherlands

11 ³ Department Population Health Sciences, Division Animals in Science and Society, Faculty of
12 Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

13 ⁴ Institute of Diagnostic Virology, Friedrich-Loeffler-Institute, Insel Riems, Germany

14 ⁵ Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands

15 ⁶ Department of Biomolecular Health Sciences, Virology Division, Faculty of Veterinary
16 Medicine, Utrecht University, the Netherlands

17

18 Corresponding authors: Corine H. GeurtsvanKessel (c.geurtsvankessel@erasmusmc.nl),

19 Carmen W.E. Embregts (c.embregts@erasmusmc.nl)

20 **Abstract**

21 Assays to measure SARS-CoV-2-specific neutralizing antibodies are important to monitor
22 seroprevalence, to study asymptomatic infections and to reveal (intermediate) hosts. A recently
23 developed assay, the surrogate virus-neutralization test (sVNT) is a quick and commercially
24 available alternative to the “gold standard” virus neutralization assay using authentic virus, and
25 does not require processing at BSL-3 level. The assay relies on the inhibition of binding of the
26 receptor binding domain (RBD) on the spike (S) protein to human angiotensin-converting
27 enzyme 2 (hACE2) by antibodies present in sera. As the sVNT does not require species- or
28 isotype-specific conjugates, it can be similarly used for antibody detection in human and animal
29 sera. In this study, we used 298 sera from PCR-confirmed COVID-19 patients and 151 sera
30 from patients confirmed with other coronavirus or other (respiratory) infections, to evaluate the
31 performance of the sVNT. To analyze the use of the assay in a One Health setting, we studied
32 the presence of RBD-binding antibodies in 154 sera from nine animal species (cynomolgus and
33 rhesus macaques, ferrets, rabbits, hamsters, cats, cattle, mink and dromedary camels). The
34 sVNT showed a moderate to high sensitivity and a high specificity using sera from confirmed
35 COVID-19 patients (91.3% and 100%, respectively) and animal sera (93.9% and 100%),
36 however it lacked sensitivity to detect low titers. Significant correlations were found between
37 the sVNT outcomes and PRNT₅₀ and the Wantai total Ig and IgM ELISAs. While species-
38 specific validation will be essential, our results show that the sVNT holds promise in detecting
39 RBD-binding antibodies in multiple species.

40

41 **Keywords** (max 6)

42 SARS-CoV-2, serology, neutralizing antibodies, surrogate virus neutralization test, animal sera

43

44 **Introduction**

45 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) likely originates from an
46 animal reservoir as a result of a direct spill-over event or via an intermediate mammalian host,
47 similar to the related zoonotic betacoronaviruses SARS-CoV and MERS-CoV [1,2].
48 Phylogenetic analysis revealed that SARS-CoV-2 is ancestrally linked to betacoronaviruses
49 found in bats [3] and pangolins [4], however, the definitive virus origin and intermediate host(s)
50 remain unidentified. Besides efficiently infecting humans, SARS-CoV-2 has been detected in
51 a wide range of animals, including farmed mink across Europe and the USA [5–7], domestic
52 animals including cats and dogs [8–10], and several zoo felids [11]. Alarming, infections in
53 all these species could be traced back to SARS-CoV-2 infected humans, indicating a risk for
54 reverse zoonotic events and possible SARS-CoV-2 animal reservoirs [7,12]. Furthermore,
55 infection experiments show that many more animal species, including non-human primates
56 [13,14], ferrets [15,16], rabbits [17], hamsters [18,19], and human angiotensin-converting
57 enzyme 2 (hACE2) transgenic mice [20] are permissive to the virus, while other animals
58 including pigs and chickens are not [21,22]. The large number of permissive species and the
59 potential risks of additional (reverse) zoonotic events clearly indicate that a One Health
60 approach is required to gain insights into the circulation of SARS-CoV-2 in humans and
61 epidemiologically connected animal host populations, which is essential for the prevention or
62 mitigation of further spread.

63 Assays to reliably detect SARS-CoV-2 specific antibodies across species are urgently needed,
64 for example to investigate seroprevalence and asymptomatic infections, for vaccination studies
65 in humans and animals, and for the identification of natural reservoirs and intermediate hosts.
66 Tremendous efforts in the rapid development of serological tools yielded a broad range of
67 assays to determine SARS-CoV-2 specific antibodies, including (high throughput) ELISAs and
68 lateral flow assays targeting various SARS-CoV-2 epitopes [23–25]. Total serum antibodies

69 are indicative for exposure, however, quantifying neutralizing antibodies is more informative.
70 A commonly used gold standard for detecting SARS-CoV-2 neutralizing antibodies is the 50-
71 percent plaque-reduction neutralization test (PRNT₅₀). This test requires handling of wild-type
72 viruses by BSL3-level trained personnel, is not suitable for high-throughput, and results are
73 available after multiple days. Furthermore, minor differences in virus stocks and cell lines
74 complicate the intra-laboratory standardization. While pseudotyped viruses allow for
75 performing PRNT₅₀ tests at a BSL-2 safety level [26,27], and recombinant nanoluciferase
76 SARS-CoV-2 allows for a rapid assay protocol [28], these assays still rely on infectious viruses
77 and cell cultures.

78 The first surrogate virus neutralization test (sVNT) was commercialized in 2020 [29]. This
79 assay relies on specific binding of recombinant SARS-CoV-2 receptor binding domain (RBD)
80 to recombinant ACE2 coated on 96-wells plates, and blocking of this binding by RBD-specific
81 serum antibodies. The assay can be performed at any BSL-2 laboratory and yields results in
82 only few hours. Furthermore, the assay allows for high sample-throughput, as samples are
83 analyzed in one defined dilution and no serial dilution is required. Validation studies showed
84 high specificity and sensitivity of the assay [29–31], however, a recent study demonstrated low
85 sensitivity in sera with low neutralizing titers and only moderate linearity with the PRNT₅₀ [32].

86 While conventional ELISAs often rely on species- and isotype-specific conjugates, the sVNT
87 assay detects RBD-binding antibodies and can potentially be used for a wide range of species.
88 In contrast to the large number of tests developed for human sera, serological SARS-CoV-2
89 assays for other species are limited to the PRNT₅₀, few multi-species ELISAs [16,33,34], and
90 mouse-, guinea pig-, rabbit-, and primate-specific competition ELISAs [35,36].

91 To date, only few studies assessed the use of the described sVNT in animals (mice, rabbits,
92 ferrets, cats and hamsters) [29,30]. While these studies showed that the sVNT is capable of
93 detecting RBD-specific antibodies in the mentioned animal species, only limited numbers of

94 SARS-CoV-2 antibody positive sera were included. Here, we evaluate the performance of the
95 sVNT on human sera using 298 serum samples from a COVID-19 patient cohort, 151 sera from
96 patients diagnosed with related human coronaviruses and other (respiratory) viruses and
97 pathogens. In addition, we investigate the use of the sVNT on 154 serum samples from nine
98 different animal species.
99

100 **Materials and methods**

101

102 **Human serum samples**

103 All human sera used in this study were collected for routine patient diagnostics. Sensitivity
104 analysis was performed using a panel of 298 sera of 165 PCR-confirmed COVID-19 patients.
105 Disease severity ranged from mild (non-hospitalized) to severe (admitted to the ICU), and
106 samples were taken at various days post disease onset (dpd), ranging from 0-74 days
107 (Supplementary table 1). Specificity analysis was performed using a panel of 151 sera from
108 individuals exposed to other human coronaviruses (HCoV-229E (n=19), HCoV-NL63 (n=18),
109 HCoV-OC43 (n=36), or MERS-CoV (n=5)), other respiratory viruses (adenovirus (n=6),
110 bocavirus (n=2), human metapneumovirus (HMPV, n=9), influenza virus A (n=10) and B
111 (n=6), human orthopneumovirus/ respiratory syncytial virus (RSV) A (n=5) and B (n=4),
112 rhinovirus (n=9), para-influenza virus 1 (n=4) and 3 (n=4), enterovirus (n=2)), or patients with
113 recent cytomegalovirus (CMV, n=4) , Epstein Barr virus (EBV, n=7) or *Mycoplasma*
114 *pneumoniae* (*M. pneumoniae*, n=1) infection. All sera were stored at -20 °C and were heat-
115 inactivated at 56 °C for 30 minutes prior to analysis.

116

117 **Animal serum samples**

118 Animal sera were obtained after natural infections or during infection or vaccination
119 experiments. In total 154 sera of nine different species (cynomolgus and rhesus macaques,
120 ferrets, rabbits, hamsters, cats, cattle, mink and dromedary camels) were included in the
121 validation study, of which 66 tested positive for SARS-CoV-2 antibodies by PRNT₅₀
122 (Supplementary table 2). SARS-CoV-2 antibody status of the cat sera was determined by a
123 pseudotype VSV neutralization (VN) assay [37]. Sera from SARS-CoV-2 negative animals

124 were included to test the specificity of the assay. A set of possible cross-reactive sera from
125 MERS-CoV infected macaques and dromedary camels was included as well.

126

127 **Ethics**

128 The use of human specimens was approved by the Erasmus MC medical ethical committee
129 (MEC approval: 2014–414), which allows the use of clinical data and left-over material from
130 the specimen delivered to our laboratory for diagnostics, unless patients have declared they
131 opted out of this scheme.

132 Animal sera were obtained as left-over material from various infection experiments or field
133 studies (mink and cats). Specific approval was obtained for each set of sera and can be found
134 in the referred articles. Additional non-human primate sera were obtained from various
135 experiments that were approved by the Dutch Central Committee for Animal Experiments
136 (license: AVD5020020209404). Mink and cat sera were obtained by a certified veterinarian
137 during a SARS-CoV-2 outbreak at a mink farm in the Netherlands.

138

139 **PRNT₅₀ / VSV pseudotype VN**

140 The 50-percent plaque-reduction neutralization test (PRNT₅₀) was used as the gold standard in
141 this study and was performed as described before [38]. The PRNT₅₀ titer was defined as the
142 reciprocal value of the highest serum dilution resulting in 50% plaque reduction. Serum titers
143 of ≥ 20 were defined as SARS-CoV-2 seropositive.

144 The pseudotype VN assay was performed as described recently [37] with some minor
145 modification: serum samples were twofold diluted (starting at 1:8) and mixed 1:1 with SARS2-
146 VSV. Mixtures were pre-incubated at 37°C for one hour and were afterwards used for
147 inoculation of cells. Twenty-four hours post infection, the cells were lysed and relative
148 luminescence units (RLU) of luciferase activity was determined. The sample neutralization

149 titers were defined by the reciprocal of the highest dilution that resulted in >50% reduction of
150 luciferase activity (IC50 titer).

151

152 **Wantai Ig/IgM**

153 Detection of anti-RBD antibodies was performed using the Wantai SARS-CoV-2 total Ig or
154 IgM ELISAs (Beijing Wantai Biological Pharmacy Enterprise), which are sandwich ELISAs
155 coated with recombinant RBD. The ELISAs were performed according to the manufacturer's
156 guidelines. The readout (OD ratio) was calculated by dividing the OD (measured at 450 nm) of
157 each sample with the OD of the calibrator that was supplied with the kit.

158

159 **Surrogate VNT**

160 RBD-binding antibodies in human and animal sera were measured with the GenScript cPass
161 SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript, the Netherlands), following
162 the manufacturer's guidelines. Briefly, serum samples (1:10 diluted) were mixed with equal
163 volumes of recombinant HRP-conjugated RBD and incubated for 30 minutes at 37 °C. One
164 hundred µL was then transferred to 96-well plates coated with recombinant hACE2 receptor
165 and incubated for 15 minutes at 37 °C. The mixture was removed, and after four automated
166 washing steps, the development solution (tetramethylbenzidine substrate, TMB) was incubated
167 for 15 minutes at room temperature, after which the stop solution was added. Absorbance was
168 measured at 450 nm and the percentage of inhibition of each sample was calculated using the
169 following formula: % inhibition = (1- (OD450 sample/ OD450 of negative control)) x 100.
170 Controls were included in duplicate, samples were analyzed in singular. Inhibition >30% was
171 regarded as a positive neutralization, as suggested by the latest validation paper [29].

172

173

174 **Statistical analysis**

175 Spearman's correlation coefficients were calculated on the sVNT inhibition percentages and

176 the log₂-transformed PNRT₅₀ titers or the ODratio for the Wantai Ig or IgM in SPSS 27 (IBM).

177 Correlation was considered significant with p values < 0.05 .

178

179 **Results and discussion**

180 The performance of the commercial sVNT was evaluated by determining the correlation
181 between the PRNT₅₀, a gold standard assay, and the sVNT. Although the initial commercial
182 sVNT guidelines included a cut-off of 20%, a recent validation paper now recommends a
183 positivity cut-off at 30% of inhibition [29]. We therefore evaluated the performance of the
184 sVNT by both a 20% and 30% cut-off (Table 1). For the discussion of our results, we will focus
185 on the evaluation with the 30% cut-off. Using the serum panel of PCR-confirmed COVID-19
186 patients we found an overall sensitivity of 91.3 and a corresponding specificity of 100%. We
187 found a strong increase in sensitivity of the assay with increasing PRNT₅₀ titers; sensitivity rose
188 from respectively 50% and 74.1% in the low-titer groups of 20 and 40, to 91.4% and above for
189 titers of 80 and higher (Table 1, Fig. 1A). 100% sensitivity was reached for sera with titers of
190 160 and above. In line with the expected rise in titer during the course of disease, we found that
191 assay sensitivity increased from 88.2 to 91.0 and 96.6 when comparing the periods between 1-
192 10, 11-21 and >21 dpd (Table 1). Overall, a significant ($p < 0.001$, with an Spearman's r of
193 0.68) correlation was observed between the two serological tests. However, the variation within
194 PRNT₅₀ groups shows that the sVNT results should be interpreted with care, since high
195 inhibition in the sVNT is not directly translatable to high PRNT₅₀ titers (Fig. 1A). Performing
196 a 30%-inhibition titration of each sample would allow a more accurate comparison of both
197 assays. However, this would drastically decrease sample throughput and increase costs, which
198 is unpreferable in diagnostic settings.

199 The results of the sVNT also showed significant correlation ($p < 0.001$) with OD ratios of the
200 Wantai SARS-CoV-2 specific total Ig or IgM ELISAs, with a Spearman's r of 0.74 and 0.67
201 for the total Ig (Fig. 1B) and IgM (Fig. 1C) Wantai ELISA, respectively. Unfortunately, the
202 high number of samples that reached the maximum value in both ELISAs might have affected
203 the correlation coefficient. Closer investigation of the sera that showed a positive PRNT₅₀ result

204 but a negative sVNT result revealed that 18 out of 21 sera were positive in the IgM Wantai and
205 20 out of 21 were positive in the total Ig Wantai. SARS-CoV-2 neutralizing antibodies that do
206 not block binding of RBD to ACE2 have been described [37], suggesting that this type of
207 antibodies might cause false negative results in the sVNT. Another risk for false negatives is
208 that this sVNT only targets RBD-binding antibodies, leaving neutralizing antibodies against
209 other domains of the S1- protein undetected [39,40].

210 The specificity of the sVNT was further investigated using a serum panel containing sera of
211 individuals diagnosed with other coronaviruses or other (respiratory) viruses or diseases. Using
212 this panel, we confirmed that the sVNT is 100% specific, as we did not find cross-reactivity
213 with any of the tested sera (Fig. 1B). Two samples were found to have an inhibition between
214 20-30%, one serum of a HCoV-229E patient and one of an adenovirus patient. Both samples
215 tested negative in the PRNT₅₀.

216 In parallel to the human sera, we assessed the performance of the sVNT in an elaborate panel
217 of animal sera that included experimental model species, but also (suspected) reservoir species
218 (Fig. 2A). Specificity of the assay was assessed using a panel of control sera from naïve animals.
219 Sera from MERS-CoV infected cynomolgus macaques and dromedary camels were included
220 to assess possible cross-reactivity. Similar to the results obtained with the human validation
221 serum panel, the sVNT showed a good performance in general, with a sensitivity of 93.9% and
222 a specificity 100%. For the rhesus macaques, ferrets, rabbits, hamsters, cats, cattle and mink we
223 observed a 100% accurate detection of (the absence of) RBD-specific antibodies in the sera of
224 SARS-CoV-2 positive and negative animals.

225 For the cynomolgus macaques two sera of SARS-CoV-2 infected animals were found to have
226 an inhibition between 20% and 30%, and a PRNT₅₀ titer of 40 and 80 (Fig. 2B). However, low
227 antibody titers were expected since these animals only showed a short period of viral shedding
228 with low levels of viral RNA in nose and trachea.

229 In agreement with the human cross-reactive serum panel, no cross-reactivity was detected in
230 serum from MERS-CoV-infected rabbits and dromedary camels. The sVNT showed a
231 sensitivity and specificity of 100% in animal sera with a PRNT₅₀ titer of 160 and above. In
232 contrast to the panel of human sera, no clear linearity was detected in the panel of animal sera
233 and large differences were observed between species. Interestingly, serum samples from ferrets,
234 rabbits and cattle with relatively low PRNT₅₀ titers (80 and below) showed a high inhibition in
235 the sVNT. Especially SARS-CoV-2-infected ferrets, where only two animals reached a PRNT₅₀
236 titer of 80, had an inhibition of above 92%. While these high levels of inhibition in sera with a
237 relatively low PRNT₅₀ is beneficial for detecting RBD-binding antibodies in a qualitative
238 manner, species-specific determination of the optimal serum dilutions is essential when the data
239 is to be interpreted (semi-)quantitatively. The control sera of the ferrets, rabbits and cattle had
240 negative sVNT outcomes, indicating that the high inhibition levels were not due to background
241 or aspecific binding. Furthermore, the wide range of species-specific endemic coronaviruses
242 complicates the design of specific serological tests [41,42], and cross-reactivity needs to be
243 examined for every targeted species. While our data shows that the sVNT detects RBD-binding
244 antibodies in nine animal species, it clearly indicates that more elaborate validation is required.
245 Validations should include higher number of sera per species, a panel of potentially cross-
246 reactive sera, and should aim at determining optimal serum dilutions and cut-off levels.

247

248 **Conclusion**

249 Our results show moderate to high sensitivity and high specificity of the sVNT for detecting
250 RBD-binding antibodies, with a 100% accuracy in sera with a PRNT₅₀ titer 160, for both human
251 and animal sera. sVNT results should be interpreted rather qualitatively than quantitatively,
252 since the results only show partial linearity with the PRNT₅₀ titers.

253 Despite the low sensitivity in detecting low titers, the sVNT still has potential use. The
254 possibility for high sample throughput makes the sVNT a suitable assay for large
255 seroprevalence studies that aim at detecting high titers, for example in vaccination trials or in
256 large scale initial testing of potential animal reservoirs. While the required titer for complete
257 protection is still under investigation, studies have shown that with a PRNT₅₀ titer of 80 and
258 above, no infectious virus could be detected in the respiratory tract [43]. It is thus to be expected
259 that threshold titers for complete protection will be in this range or higher, and as a consequence
260 the sVNT can be a valuable assay to assess protection in a qualitative manner. However, the
261 sVNT does not serve as a full replacement of gold standard tests that use authentic virus, given
262 that it lacks the sensitivity to detect low titers and only targets RBD-binding antibodies.

263 Our evaluation shows that the sVNT also has potential use for detecting RBD-specific
264 antibodies in animal sera, but we observed large species-dependent differences in sensitivity of
265 the test. While in some species we observed high sVNT results in sera with low PRNT₅₀ (ferrets,
266 rabbit, cattle), sera with low to moderate PRNT₅₀ from other species resulted in negative or low
267 sVNT results (cynomolgus macaques). More elaborate species-specific validations are required
268 to determine the true potential of the sVNT.

269

270

271 **Acknowledgments**

272 The authors acknowledge Anouskha Comvalius, Djenolan van Mourik, Jeroen Ijpelaar and

273 Georgina Arron for performing the PRNT₅₀, and Susanne Bogers for the sVNT testing. Robert

274 Jan Molenaar is acknowledged for supplying the mink sera that was included in this study.

275

276 **Conflict of interest**

277 The authors declare that there is no conflict of interest.

278

279 **References**

- 280 [1] K.G. Andersen, A. Rambaut, W.I. Lipkin, E.C. Holmes, R.F. Garry, The proximal
281 origin of SARS-CoV-2, *Nat. Med.* 26 (2020) 450–452. doi:10.1038/s41591-020-0820-
282 9.
- 283 [2] J. Zhao, W. Cui, B.P. Tian, The Potential Intermediate Hosts for SARS-CoV-2, *Front.*
284 *Microbiol.* 11 (2020) 1–11. doi:10.3389/fmicb.2020.580137.
- 285 [3] P. Zhou, X. Lou Yang, X.G. Wang, B. Hu, L. Zhang, W. Zhang, H.R. Si, Y. Zhu, B.
286 Li, C.L. Huang, H.D. Chen, J. Chen, Y. Luo, H. Guo, R. Di Jiang, M.Q. Liu, Y. Chen,
287 X.R. Shen, X. Wang, X.S. Zheng, K. Zhao, Q.J. Chen, F. Deng, L.L. Liu, B. Yan, F.X.
288 Zhan, Y.Y. Wang, G.F. Xiao, Z.L. Shi, A pneumonia outbreak associated with a new
289 coronavirus of probable bat origin, *Nature.* 579 (2020) 270–273. doi:10.1038/s41586-
290 020-2012-7.
- 291 [4] K. Xiao, J. Zhai, Y. Feng, N. Zhou, X. Zhang, J.J. Zou, N. Li, Y. Guo, X. Li, X. Shen,
292 Z. Zhang, F. Shu, W. Huang, Y. Li, Z. Zhang, R.A. Chen, Y.J. Wu, S.M. Peng, M.
293 Huang, W.J. Xie, Q.H. Cai, F.H. Hou, W. Chen, L. Xiao, Y. Shen, Isolation of SARS-
294 CoV-2-related coronavirus from Malayan pangolins, *Nature.* 583 (2020) 286–289.
295 doi:10.1038/s41586-020-2313-x.
- 296 [5] N. Oreshkova, R.J. Molenaar, S. Vreman, F. Harders, B.B. Oude Munnink, R.W.H.
297 Van Der Honing, N. Gerhards, P. Tolsma, R. Bouwstra, R.S. Sikkema, M.G.J. Tacken,
298 M.M.T. De Rooij, E. Weesendorp, M.Y. Engelsma, C.J.M. Brusckke, L.A.M. Smit, M.
299 Koopmans, W.H.M. Van Der Poel, A. Stegeman, SARS-CoV-2 infection in farmed
300 minks, the Netherlands, April and May 2020, *Eurosurveillance.* 25 (2020) 1–7.
301 doi:10.2807/1560-7917.ES.2020.25.23.2001005.
- 302 [6] OIE, COVID-19 Events in animals, (2020). [https://www.oie.int/en/scientific-](https://www.oie.int/en/scientific-expertise/specific-information-and-recommendations/questions-and-answers-on-)
303 [expertise/specific-information-and-recommendations/questions-and-answers-on-](https://www.oie.int/en/scientific-expertise/specific-information-and-recommendations/questions-and-answers-on-)

- 304 2019novel-coronavirus/events-in-animals/ (accessed December 10, 2020).
- 305 [7] B.B. Oude Munnink, R.S. Sikkema, D.F. Nieuwenhuijse, R.J. Molenaar, E. Munger, R.
306 Molenkamp, A. van der Spek, P. Tolsma, A. Rietveld, M. Brouwer, N. Bouwmeester-
307 Vincken, F. Harders, R. Hakze-van der Honing, M.C.A. Wegdam-Blans, R.J.
308 Bouwstra, C. GeurtsvanKessel, A.A. van der Eijk, F.C. Velkers, L.A.M. Smit, A.
309 Stegeman, W.H.M. van der Poel, M.P.G. Koopmans, Transmission of SARS-CoV-2 on
310 mink farms between humans and mink and back to humans, *Science* (80-.). 371 (2020)
311 172–177. doi:10.1126/science.abe5901.
- 312 [8] A.V. Neira, B. Brito, B. Agüero, F. Berrios, V. Valdés, A. Gutierrez, N. Ariyama, P.
313 Espinoza, P. Retamal, E.C. Holmes, A.S. Gonzalez-reiche, Z. Khan, A. Van De
314 Guchte, J. Dutta, L. Miorin, SARS-CoV-2 in naturally infected cats present a shorter
315 shedding pattern compared to their owners., *MedRxiv*. (2020).
316 doi:10.1101/2020.10.31.20220608.
- 317 [9] E.M. Leroy, M. Ar Gouilh, J. Brugère-Picoux, The risk of SARS-CoV-2 transmission
318 to pets and other wild and domestic animals strongly mandates a one-health strategy to
319 control the COVID-19 pandemic, *One Heal.* 10 (2020) 4–7.
320 doi:10.1016/j.onehlt.2020.100133.
- 321 [10] N.N. Gaudreault, J.D. Trujillo, M. Carossino, D.A. Meekins, I. Morozov, D.W.
322 Madden, S. V. Indran, D. Bold, V. Balaraman, T. Kwon, B.L. Artiaga, K. Cool, A.
323 García-Sastre, W. Ma, W.C. Wilson, J. Henningson, U.B.R. Balasuriya, J.A. Richt,
324 SARS-CoV-2 infection, disease and transmission in domestic cats, *Emerg. Microbes*
325 *Infect.* 9 (2020) 2322–2332. doi:10.1080/22221751.2020.1833687.
- 326 [11] D. McAloose, M. Laverack, L. Wang, M.L. Killian, L.C. Caserta, F. Yuan, P.K.
327 Mitchell, K. Queen, M.R. Mauldin, B.D. Cronk, S.L. Bartlett, J.M. Sykes, S. Zec, T.
328 Stokol, K. Ingerman, M.A. Delaney, R. Fredrickson, M. Ivančić, M. Jenkins-Moore, K.

- 329 Mazingo, K. Franzen, N.H. Bergeson, L. Goodman, H. Wang, Y. Fang, C. Olmstead,
330 C. McCann, P. Thomas, E. Goodrich, F. Elvinger, D.C. Smith, S. Tong, S. Slavinski,
331 P.P. Calle, K. Terio, M.K. Torchetti, D.G. Diel, From people to panthera: Natural sars-
332 cov-2 infection in tigers and lions at the bronx zoo, MBio. 11 (2020) 1–13.
333 doi:10.1128/mBio.02220-20.
- 334 [12] S. Sooksawasdi, N. Ayudhya, T. Kuiken, Reverse Zoonosis of COVID-19 : Lessons
335 From the 2009 Influenza Pandemic, Vet. Pathol. (2020).
336 doi:10.1177/0300985820979843.
- 337 [13] B. Rockx, T. Kuiken, S. Herfst, T. Bestebroer, M.M. Lamers, B.B.O. Munnink, D. De
338 Meulder, G. Van Amerongen, J. Van Den Brand, N.M.A. Okba, D. Schipper, P. Van
339 Run, L. Leijten, R. Sikkema, E. Verschoor, B. Verstrepen, W. Bogers, J. Langermans,
340 J. Langermans, C. Drosten, M.F. Van Vliissingen, R. Fouchier, R. De Swart, M.
341 Koopmans, B.L. Haagmans, Comparative pathogenesis of COVID-19, MERS, and
342 SARS in a nonhuman primate model, Science (80-.). 368 (2020) 1012–1015.
343 doi:10.1126/science.abb7314.
- 344 [14] V.J. Munster, F. Feldmann, B.N. Williamson, N. Van Doremalen, L. Pérez-pérez, J.
345 Schulz, K. Meade-white, A. Okumura, B. Brumbaugh, V.A. Avanzato, R. Rosenke, W.
346 Patrick, G. Saturday, D. Scott, E.R. Fischer, E. De Wit, Respiratory disease and virus
347 shedding in rhesus macaques inoculated with SARS-CoV-2, Nature. 585 (2020) 268–
348 272. doi:10.1038/s41586-020-2324-7.Respiratory.
- 349 [15] Y. Il Kim, S.G. Kim, S.M. Kim, E.H. Kim, S.J. Park, K.M. Yu, J.H. Chang, E.J. Kim,
350 S. Lee, M.A.B. Casel, J. Um, M.S. Song, H.W. Jeong, V.D. Lai, Y. Kim, B.S. Chin,
351 J.S. Park, K.H. Chung, S.S. Foo, H. Poo, I.P. Mo, O.J. Lee, R.J. Webby, J.U. Jung,
352 Y.K. Choi, Infection and Rapid Transmission of SARS-CoV-2 in Ferrets, Cell Host
353 Microbe. 27 (2020) 704-709.e2. doi:10.1016/j.chom.2020.03.023.

- 354 [16] J. Shi, Z. Wen, G. Zhong, H. Yang, C. Wang, B. Huang, R. Liu, X. He, L. Shuai, Z.
355 Sun, Y. Zhao, P. Liu, L. Liang, P. Cui, J. Wang, X. Zhang, Y. Guan, W. Tan, G. Wu,
356 H. Chen, Z. Bu, Z. Bu, Susceptibility of ferrets, cats, dogs, and other domesticated
357 animals to SARS-coronavirus 2, *Science* (80-.). 368 (2020) 1016–1020.
358 doi:10.1126/science.abb7015.
- 359 [17] A.Z. Mykytyn, M.M. Lamers, N.M. Okba, T.I. Breugem, P.B. van den Doel, P. van
360 Run, G. van Amerongen, L. de Waal, P. Koopmans, K.J. Stittelaar, J.M. van den
361 Brand, B.L. Haagmans, L. de Waal, K. Stittelaar, Susceptibility of rabbits to SARS-
362 CoV-2, *BioRxiv*. (2020) 2020.08.27.263988. doi:10.1080/22221751.2020.1868951.
- 363 [18] S.F. Sia, L.M. Yan, A.W.H. Chin, K. Fung, K.T. Choy, A.Y.L. Wong, P.
364 Kaewpreedee, R.A.P.M. Perera, L.L.M. Poon, J.M. Nicholls, M. Peiris, H.L. Yen,
365 Pathogenesis and transmission of SARS-CoV-2 in golden hamsters, *Nature*. 583 (2020)
366 834–838. doi:10.1038/s41586-020-2342-5.
- 367 [19] M. Imai, K. Iwatsuki-Horimoto, M. Hatta, S. Loeber, P.J. Halfmann, N. Nakajima, T.
368 Watanabe, M. Ujie, K. Takahashi, M. Ito, S. Yamada, S. Fan, S. Chiba, M. Kuroda, L.
369 Guan, K. Takada, T. Armbrust, A. Balogh, Y. Furusawa, M. Okuda, H. Ueki, A.
370 Yasuhara, Y. Sakai-Tagawa, T.J.S. Lopes, M. Kiso, S. Yamayoshi, N. Kinoshita, N.
371 Ohmagari, S.I. Hattori, M. Takeda, H. Mitsuya, F. Krammer, T. Suzuki, Y. Kawaoka,
372 Syrian hamsters as a small animal model for SARS-CoV-2 infection and
373 countermeasure development, *Proc. Natl. Acad. Sci. U. S. A.* 117 (2020) 16587–16595.
374 doi:10.1073/pnas.2009799117.
- 375 [20] L. Bao, W. Deng, B. Huang, H. Gao, J. Liu, L. Ren, Q. Wei, P. Yu, Y. Xu, F. Qi, Y.
376 Qu, F. Li, Q. Lv, W. Wang, J. Xue, S. Gong, M. Liu, G. Wang, S. Wang, Z. Song, L.
377 Zhao, P. Liu, L. Zhao, F. Ye, H. Wang, W. Zhou, N. Zhu, W. Zhen, H. Yu, X. Zhang,
378 L. Guo, L. Chen, C. Wang, Y. Wang, X. Wang, Y. Xiao, Q. Sun, H. Liu, F. Zhu, C.

- 379 Ma, L. Yan, M. Yang, J. Han, W. Xu, W. Tan, X. Peng, Q. Jin, G. Wu, C. Qin, The
380 pathogenicity of SARS-CoV-2 in hACE2 transgenic mice, *Nature*. 583 (2020) 830–
381 833. doi:10.1038/s41586-020-2312-y.
- 382 [21] K. Schlottau, M. Rissmann, A. Graaf, J. Schön, J. Sehl, C. Wylezich, D. Höper, T.C.
383 Mettenleiter, A. Balkema-Buschmann, T. Harder, C. Grund, D. Hoffmann, A.
384 Breithaupt, M. Beer, SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an
385 experimental transmission study, *The Lancet Microbe*. 1 (2020) e218–e225.
386 doi:10.1016/s2666-5247(20)30089-6.
- 387 [22] J. Vergara-Alert, J. Rodon, J. Carrillo, N. Te, N. Izquierdo-Useros, M.L. Rodríguez de
388 la Concepción, C. Ávila-Nieto, V. Guallar, A. Valencia, G. Cantero, J. Blanco, B.
389 Clotet, A. Bensaid, J. Segalés, Pigs are not susceptible to SARS-CoV-2 infection but
390 are a model for viral immunogenicity studies, *Transbound. Emerg. Dis.* (2020) 1–5.
391 doi:10.1111/tbed.13861.
- 392 [23] C.L. Charlton, J.N. Kanji, K. Johal, A. Bailey, S.S. Plitt, C. MacDonald, A. Kunst, E.
393 Buss, L.E. Burnes, K. Fonseca, B.M. Berenger, K. Schnabl, J. Hu, W. Stokes, N.
394 Zelyas, G. Tipples, Evaluation of six commercial mid- To high-volume antibody and
395 six point-of-care lateral flow assays for detection of SARS-CoV-2 antibodies, *J. Clin.*
396 *Microbiol.* 58 (2020) 1–12. doi:10.1128/JCM.01361-20.
- 397 [24] T. Nicol, C. Lefeuvre, O. Serri, A. Pivert, F. Joubaud, V. Dubée, A. Kouatchet, A.
398 Ducancelle, F. Lunel-Fabiani, H. Le Guillou-Guillemette, Assessment of SARS-CoV-2
399 serological tests for the diagnosis of COVID-19 through the evaluation of three
400 immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid
401 lateral flow immunoassay (NG Biotech), *J. Clin. Virol.* 129 (2020) 104511.
402 doi:10.1016/j.jcv.2020.104511.
- 403 [25] C.H. GeurtsvanKessel, N.M.A. Okba, Z. Igloi, S. Bogers, C.W.E. Embregts, B.M.

- 404 Laksono, L. Leijten, C. Rokx, B. Rijnders, J. Rahamat-Langendoen, J.P.C. van den
405 Akker, J.J.A. van Kampen, A.A. van der Eijk, R.S. van Binnendijk, B. Haagmans, M.
406 Koopmans, An evaluation of COVID-19 serological assays informs future diagnostics
407 and exposure assessment, *Nat. Commun.* 11 (2020) 1–5. doi:10.1038/s41467-020-
408 17317-y.
- 409 [26] J. Nie, Q. Li, J. Wu, C. Zhao, H. Hao, H. Liu, L. Zhang, L. Nie, H. Qin, M. Wang, Q.
410 Lu, X. Li, Q. Sun, J. Liu, C. Fan, W. Huang, M. Xu, Y. Wang, Establishment and
411 validation of a pseudovirus neutralization assay for SARS-CoV-2, *Emerg. Microbes*
412 *Infect.* 9 (2020) 680–686. doi:10.1080/22221751.2020.1743767.
- 413 [27] F. Zettl, T.L. Meister, T. Vollmer, B. Fischer, J. Steinmann, A. Krawczyk, P. V'kovski,
414 D. Todt, E. Steinmann, S. Pfaender, G. Zimmer, Rapid quantification of SARS-CoV-2-
415 neutralizing antibodies using propagation-defective vesicular stomatitis virus
416 pseudotypes, *Vaccines.* 8 (2020) 1–13. doi:10.3390/vaccines8030386.
- 417 [28] X. Xie, A.E. Muruato, X. Zhang, K.G. Lokugamage, C.R. Fontes-Garfias, J. Zou, J.
418 Liu, P. Ren, M. Balakrishnan, T. Cihlar, C.T.K. Tseng, S. Makino, V.D. Menachery,
419 J.P. Billello, P.Y. Shi, A nanoluciferase SARS-CoV-2 for rapid neutralization testing
420 and screening of anti-infective drugs for COVID-19, *Nat. Commun.* 11 (2020) 1–11.
421 doi:10.1038/s41467-020-19055-7.
- 422 [29] C.W. Tan, W.N. Chia, X. Qin, P. Liu, M.I.C. Chen, C. Tiu, Z. Hu, V.C.W. Chen, B.E.
423 Young, W.R. Sia, Y.J. Tan, R. Foo, Y. Yi, D.C. Lye, D.E. Anderson, L.F. Wang, A
424 SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage
425 of ACE2–spike protein–protein interaction, *Nat. Biotechnol.* 38 (2020) 1073–1078.
426 doi:10.1038/s41587-020-0631-z.
- 427 [30] R.A.P.M. Perera, R. Ko, O.T.Y. Tsang, D.S.C. Hui, M.Y.M. Kwan, C.J. Brackman,
428 E.M.W. To, H. Yen, K. Leung, S.M.S. Cheng, K.H. Chan, K.C.K. Chan, K.-C. Li, L.

- 429 Saif, V.R. Barrs, J.T. Wu, T.H.C. Sit, L.L.M. Poon, M. Peiris, Evaluation of a SARS-
430 CoV-2 surrogate virus neutralization test for detection of antibody in human, canine,
431 cat and hamster sera., *J. Clin. Microbiol.* (2020). doi:10.1128/jcm.02504-20.
- 432 [31] C. von Rhein, T. Scholz, L. Henss, R. Kronstein-Wiedermann, T. Schwarz, R.N.
433 Rodionov, V.M. Corman, T. Tonn, B.S. Schnierle, Comparison of potency assays to
434 assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent
435 plasma, *J. Virol. Methods.* (2020). doi:10.1016/j.jviromet.2020.114031.
- 436 [32] B. Meyer, J. Reimerink, G. Torriani, F. Brouwer, G.J. Godeke, S. Yerly, M.
437 Hoogerwerf, N. Vuilleumier, L. Kaiser, I. Eckerle, C. Reusken, Validation and clinical
438 evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT), *Emerg.*
439 *Microbes Infect.* 9 (2020) 2394–2403. doi:10.1080/22221751.2020.1835448.
- 440 [33] K. Wernike, A. Aebischer, A. Michelitsch, D. Hoffmann, C. Freuling, A. Balkema-
441 Buschmann, A. Graaf, T. Müller, N. Osterrieder, M. Rissmann, D. Rubbenstroth, C.
442 Schulz, J. Trimpert, L. Ulrich, A. Volz, T. Mettenleiter, M. Beer, Multi-species ELISA
443 for the detection of antibodies against SARS-CoV-2 in animals, *Transbound. Emerg.*
444 *Dis.* (2020). doi:10.1111/tbed.13926.
- 445 [34] J. Deng, Y. Jin, Y. Liu, J. Sun, L. Hao, J. Bai, T. Huang, D. Lin, Y. Jin, K. Tian,
446 Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild
447 animals excludes intermediate hosts of 35 different species of animals, *Transbound.*
448 *Emerg. Dis.* 67 (2020) 1745–1749. doi:10.1111/tbed.13577.
- 449 [35] S.N. Walker, N. Chokkalingam, E.L. Reuschel, M. Purwar, Z. Xu, E.N. Gary, K.Y.
450 Kim, M. Helble, K. Schultheis, J. Walters, S. Ramos, K. Muthumani, T.R.F. Smith,
451 K.E. Broderick, P. Tebas, A. Patel, D.B. Weiner, D.W. Kulp, SARS-CoV-2 Assays to
452 Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated
453 Animals and Infected Patients, *J. Clin. Microbiol.* 58 (2020) 1–13.

454 doi:10.1128/JCM.01533-20.

455 [36] R.D. de Vries, K.S. Schmitz, F.T. Bovier, D. Noack, B.L. Haagmans, S. Biswas, B.

456 Rockx, S.H. Gellman, C.A. Alabi, R.L. de Swart, A. MOSCONA, M. Porotto,

457 Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2

458 transmission in ferrets, *Science* (80-.). (2021) 2020.11.04.361154.

459 doi:10.1126/science.abf4896.

460 [37] C. Wang, W. Li, D. Drabek, N.M.A. Okba, R. van Haperen, A.D.M.E. Osterhaus,

461 F.J.M. van Kuppeveld, B.L. Haagmans, F. Grosveld, B.J. Bosch, A human monoclonal

462 antibody blocking SARS-CoV-2 infection, *Nat. Commun.* 11 (2020) 1–6.

463 doi:10.1038/s41467-020-16256-y.

464 [38] N.M.A. Okba, M.A. Müller, W. Li, C. Wang, C.H. Geurtsvankessel, V.M. Corman,

465 M.M. Lamers, R.S. Sikkema, E. De Bruin, F.D. Chandler, Y. Yazdanpanah, Q. Le

466 Hingrat, D. Descamps, N. Houhou-Fidouh, C.B.E.M. Reusken, B.J. Bosch, C. Drosten,

467 M.P.G. Koopmans, B.L. Haagmans, Severe Acute Respiratory Syndrome Coronavirus

468 2-Specific Antibody Responses in Coronavirus Disease Patients, *Emerg. Infect. Dis.* 26

469 (2020) 1478–1488. doi:10.3201/eid2607.200841.

470 [39] L. Liu, P. Wang, M.S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J.F.W. Chan, V. Sahi,

471 A. Figueroa, X. V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.Y.

472 Yuen, P.D. Kwong, J.G. Sodroski, M.T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D.D.

473 Ho, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike,

474 *Nature.* 584 (2020) 450–456. doi:10.1038/s41586-020-2571-7.

475 [40] X. Chi, R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong, Y.

476 Yang, Z. Chen, Y. Guo, J. Zhang, Y. Li, X. Song, Y. Chen, L. Xia, L. Fu, L. Hou, J.

477 Xu, C. Yu, J. Li, Q. Zhou, W. Chen, A neutralizing human antibody binds to the N-


478 terminal domain of the Spike protein of SARS-CoV-2, *Science* (80-.). 369 (2020)

- 479 650–655. doi:10.1126/science.abc6952.
- 480 [41] A.N. Vlasova, X. Zhang, M. Hasoksuz, H.S. Nagesha, L.M. Haynes, Y. Fang, S. Lu,
481 L.J. Saif, Two-Way Antigenic Cross-Reactivity between Severe Acute Respiratory
482 Syndrome Coronavirus (SARS-CoV) and Group 1 Animal CoVs Is Mediated through
483 an Antigenic Site in the N-Terminal Region of the SARS-CoV Nucleoprotein, *J. Virol.*
484 81 (2007) 13365–13377. doi:10.1128/jvi.01169-07.
- 485 [42] Z.F. Sun, X.J. Meng, Antigenic Cross-Reactivity between the Nucleocapsid Protein of
486 Severe Acute Respiratory Syndrome (SARS) Coronavirus and Polyclonal Antisera of
487 Antigenic Group I Animal Coronaviruses: Implication for SARS Diagnosis [2], *J. Clin.*
488 *Microbiol.* 42 (2004) 2351–2352. doi:10.1128/JCM.42.5.2351-2352.2004.
- 489 [43] J. van Kampen, D. van de Vijver, P. Fraaij, B. Haagmans, M. Lamers, N. Okba, J. van
490 den Akker, H. Endeman, D. Gommers, J. Cornelissen, R. Hoek, M. van der Eerden, D.
491 Hesselink, H. Metselaar, A. Verbon, J. de Steenwinkel, G. Aron, E. van Gorp, S. van
492 Boheemen, J. Voermans, C. Boucher, R. Molenkamp, M. Koopmans, C.
493 Geurtsvankessel, A. van der Eijk, Shedding of infectious virus in hospitalized patients
494 with coronavirus disease-2019 (COVID-19): duration and key determinants, *Nat.*
495 *Commun.* 12 (2021). doi:10.1101/2020.06.08.20125310.
- 496 [44] B.L. Haagmans, D. Noack, N.M.A. Okba, W. Li, T. Besteboer, R. de Vries, S. Herfst,
497 D. de Meulder, P. van Run, M.M. Lamers, B. Rijnders, C. Rokx, F. van Kuppeveld, F.
498 Grosveld, D. Drabek, C. GeurtsvanKessel, M. Koopmans, B.-J. Bosch, B. Rockx,
499 SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract
500 disease in a hamster model, *BioRxiv.* (2020). doi:10.1101/2020.08.24.264630.
- 501 [45] L. Ulrich, K. Wernike, D. Hoffmann, T.C. Mettenleiter, M. Beer, Experimental
502 infection of cattle with SARS-CoV-2, *Emerg. Infect. Dis.* 26 (2020) 2979–2981.
503 doi:10.3201/EID2612.203799.

504 [46] B.L. Haagmans, S.H.S. Al Dhahiry, C.B.E.M. Reusken, V.S. Raj, M. Galiano, R.
505 Myers, G.J. Godeke, M. Jonges, E. Farag, A. Diab, H. Ghobashy, F. Alhajri, M. Al-
506 Thani, S.A. Al-Marri, H.E. Al Romaihi, A. Al Khal, A. Bermingham, A.D.M.E.
507 Osterhaus, M.M. AlHajri, M.P.G. Koopmans, Middle East respiratory syndrome
508 coronavirus in dromedary camels: An outbreak investigation, *Lancet Infect. Dis.* 14
509 (2014) 140–145. doi:10.1016/S1473-3099(13)70690-X.
510
511


512 **Figures**

513



514

515 Fig. 1. sVNT results using the human validation panel containing confirmed COVID-19
 516 patients compared to the PRNT₅₀ (A), the total Ig Wantai ELISA (B) or the IgM Wantai ELISA
 517 (C). sVNT results using the cross-reactive human serum panel are shown in (D). Each dot
 518 represents an individual serum. Dotted grey lines indicate the suggested cut-off values for the
 519 presented assays. The grey lines in (A), (B) and (C) show the Spearman's correlation coefficient
 520 (r) and its confidence interval (grey area) of the PRNT₅₀ / Wantai ELISAs and the sVNT.
 521



522

523 Fig. 2. sVNT results obtained with sera of SARS-CoV-2-infected animals, MERS-CoV-
 524 infected animals or control animals, grouped by animal species and seroconversion status
 525 (positive vs. negative, (A)), or PRNT₅₀ titer (B). Each dot represents an individual serum.
 526 Dotted horizontal lines indicate the suggested 20% and 30% inhibition cut-off values. Cats were
 527 excluded in (B) since no PRNT₅₀ were available.
 528

529

530

531

532 **Tables**

533 Table 1: Sensitivity and specificity analysis of the sVNT using a 20% inhibition cut-off [upper part] or 30%
 534 cut-off of inhibition [lower part].
 535

	Group	All	Dpd				Titers PRNT ₅₀									
			Un-known	<11	11-21	>21	<20	20	40	80	160	320	640	1280	2560	>2560
PRNT ₅₀ /sVNT	+/+	226	22	27	63	114	0	12	23	34	33	26	35	29	23	11
	+/-	15	2	7	4	2	0	10	4	1	0	0	0	0	0	0
	-/+	3	0	1	0	2	3	0	0	0	0	0	0	0	0	0
	-/-	54	5	31	16	2	54	0	0	0	0	0	0	0	0	0
	n samples	298	29	66	83	120	57	22	27	35	33	26	35	29	23	11
	n patients	165	27	31	48	121										
Sensitivity [%]		93.8	91.7	79.4	94.0	98.3	54.5	85.2	97.1	100	100	100	100	100	100	100
Specificity [%]		94.7		96.9	100.0	50.0	94.7									

	Group	All	Dpd				Titers PRNT ₅₀									
			Unknown	<11	11-21	>21	<20	20	40	80	160	320	640	1280	2560	>2560
PRNT ₅₀ /sVNT	+/+	220	22	30	61	112	0	11	20	32	33	26	35	29	23	11
	+/-	21	2	4	6	4	0	11	7	3	0	0	0	0	0	0
	-/+	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	-/-	57	5	32	16	4	57	0	0	0	0	0	0	0	0	0
	n samples	298	29	66	83	120	57	22	27	35	33	26	35	29	23	11
	n patients	165	27	31	48	121										
Sensitivity [%]		91.3	91.7	88.2	91.0	96.6	50.0	74.1	91.4	100	100	100	100	100	100	100
Specificity [%]		100	100	100	100	100	100									

536

537

538 Table 2. Sensitivity and specificity analysis of the sVNT using an animal serum panel of nine
 539 different species, including SARS-CoV and MERS-CoV positive animals and control animals.
 540

	SARS-CoV-2			
	Seropositive		Seronegative	
	20%	30%	20%	30%
Cynomolgus macaques	11/13	9/13	10/10	10/10
Rhesus macaques	9/9	9/9	10/10	10/10
Ferrets	16/16	16/16	11/11	11/11
Rabbits	7/7	7/7	14/14	14/14
Hamsters	4/4	4/4	4/4	4/4
Cats	6/6	6/6	9/10	10/10
Cattle	1/1	1/1	10/10	10/10
Mink	10/10	10/10	-	-
MERS-CoV-seropositive				
Dromedary camels			13/13	13/13
Cynomolgus macaques			2/2	2/2
	Sensitivity		Specificity	
	20%	30%	20%	30%
All data	97.0	93.9	99.07	100
PRNT ₅₀ 20-80	92.9	85.7		
PRNT ₅₀ >80	100	100		

541

542

543 **Supplementary tables**

544

545 Supplementary table 1. Overview of the human COVID-19 validation serum panel.

	N	Age	Sex			Dpd	Outcome		
		Mean [range]	Female	Male	Unknown	Mean [range]*	Discharged	Deceased	Unknown
All	298	53 [15-90]	61	216	21	26 [0-74]	94	48	156
Mild	132	51 [15-66]	25	88	19	25 [0-74]	2	0	130
Ward	61	52 [25-90]	14	45	2	25 [2-65]	23	19	19
ICU	105	52 [17-83]	22	83	0	24 [0-41]	69	29	7

546

547 * 29 samples had an unknown dpd

548

549

550

551

552 Supplementary table 2. Overview of sera included in the animal serum validation panel.

	SARS-CoV-2	Control	Other	Total	Reference
Cynomolgus macaques	13	14	2 [MERS-CoV]	29	[13, unpublished]
Rhesus macaques	9	10		19	unpublished
Ferrets	16	11		27	[36, unpublished]
Rabbits	7	14		21	[17,33]
Hamsters	4	4		8	[44]
Cats	6	10		16	[5]
Cattle	1	10		11	[45]
Mink	10	0		10	unpublished
Dromedary camels	0	0	13 [MERS-CoV]	13	[46]
	66	73	15	154	

553